Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Oostrom, J.C.H.
Right arrow Articles by Leenders, K. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Oostrom, J.C.H.
Right arrow Articles by Leenders, K. L.
NEUROLOGY 2005;65:941-943
© 2005 American Academy of Neurology
Brief Communications

Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease

J.C.H. van Oostrom, MD, R. P. Maguire, PhD, C. C. Verschuuren-Bemelmans, MD, L. Veenma-van der Duin, J. Pruim, MD, PhD, R. A.C. Roos, MD, PhD and K. L. Leenders, MD, PhD

From the Movement Disorder Unit, Department of Neurology, (Drs. Van Oostrom, Maguire, and Leenders, L. Veenma-Van der Duin), Department of Clinical Genetics (Dr. Verschuuren-Bemelmans), and PET Center (Dr. Pruim), Groningen University Medical Center, Groningen; and Department of Neurology (Dr. Roos), Leiden University Medical Center, Leiden, The Netherlands.

Address correspondence and reprint requests to Dr Leenders, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands; e-mail: k.l.leenders{at}neuro.umcg.nl

Among 27 preclinical carriers of the Huntington disease mutation (PMC), the authors found normal striatal values for MRI volumetry in 88% and for fluorodesoxyglucose PET metabolic index in 67%. Raclopride PET binding potential (RAC-BP) was decreased in 50% and correlated with increases in the product of age and CAG repeat length (p < 0.0005). Dopamine D2 receptor availability measured by RAC-BP seems the most sensitive indicator of early neuronal impairment in PMC.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the September 27 issue to find the link for this article.

Supported by the Prinses Beatrix Fonds.

Disclosure: The authors report no conflicts of interest.

Received December 3, 2004. Accepted in final form May 13, 2005.




This article has been cited by other articles:


Home page
 BrainHome page
A. Feigin, C. Tang, Y. Ma, P. Mattis, D. Zgaljardic, M. Guttman, J. S. Paulsen, V. Dhawan, and D. Eidelberg
Thalamic metabolism and symptom onset in preclinical Huntington's disease
Brain, November 1, 2007; 130(11): 2858 - 2867.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. Y. Heng, S. J. Tallaksen-Greene, P. J. Detloff, and R. L. Albin
Longitudinal Evaluation of the Hdh(CAG)150 Knock-In Murine Model of Huntington's Disease
J. Neurosci., August 22, 2007; 27(34): 8989 - 8998.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
Y. F. Tai, N. Pavese, A. Gerhard, S. J. Tabrizi, R. A. Barker, D. J. Brooks, and P. Piccini
Microglial activation in presymptomatic Huntington's disease gene carriers
Brain, July 1, 2007; 130(7): 1759 - 1766.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.